Shanghai RAAS Blood Products Co., Ltd. (SHE:002252)

Market Cap	44.12B
Revenue (ttm)	7.88B
Net Income (ttm)	1.98B
Shares Out	6.60B
EPS (ttm)	0.30
PE Ratio	22.41
Forward PE	18.82
Dividend	0.07 (0.99%)
Ex-Dividend Date	Jul 14, 2025

Volume	20,973,868
Average Volume	43,463,424
Open	6.81
Previous Close	6.69
Day's Range	6.65 - 6.81
52-Week Range	6.50 - 8.68
Beta	0.40
RSI	34.83
Earnings Date	Aug 30, 2025

About SHE:002252

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 3,350
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002252

Financial Performance

In 2024, SHE:002252's revenue was 8.18 billion, an increase of 2.67% compared to the previous year's 7.96 billion. Earnings were 2.19 billion, an increase of 23.25%.